Thelansis

  Endometrial cancer is the most common gynecological cancer and typically carries a favorable prognosis, primarily due to the high percentage of patients diagnosed at early stages (75% at stage I and 13% at stage II). Relapse risk in endometrial cancer patients varies, ranging from 10–15% for early-stage disease to 40–70% for advanced stages, with most recurrences happening within the initial 3 years post-diagnosis. Median survival post-recurrence rarely surpasses 12 months, with time to relapse and a number of relapse sites independently affecting survival. Some patients may benefit from hormonal manipulation, systemic chemotherapies, or a combination of volume-directed radiotherapy and systemic chemotherapy, depending on residual disease post-surgery, recurrence site, prior therapies, and treatment intent (curative or palliative). Surgery, particularly salvage cytoreductive surgery, is primarily employed for central pelvic recurrences. Patients with advanced-stage disease or a...